HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

Positive Phase III Results for Narcolepsy Drug with Low Cardiovascular Risk

by admin | Oct 8, 2019 | Clinical Trials

The narcolepsy drug, developed by Irish company Jazz Pharmaceuticals, has a lower salt content than the current treatment Xyrem, making it more suitable for patients at risk of cardiovascular disease.  In a 200-patient phase III trial that finished in July, Jazz...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies bacteria binx health Biosimilar Blood Filter Cancer cardiovascular cell therapy CE Mark clinical trial colorectal cancer Diagnostics Digital Health Drug Discovery ExThera Medical FDA FDA approval funding fundraising glycosylation Halodoc HIV Innovation Licensing M&A medical device medtech microbial microbial DNA microbial RNA microbiome Neuro Novartis pharma Pharming Prescient Metabiomics robots software Therapeutics Therapy USA VIrology women health

Home
Activities
Our Team
Contact Us

         contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.